Toripalimab is the first approved domestic monoclonal antibody targeting PD-1 in China, which can block the PD-1 of T lymphocytes, block its binding to PD-L1 on the surface of tumor cells, relieve the immune suppression of T cells by tumor cells, and enable immune cells to regain their anti-tumor cell immune role and kill tumor cells (25, 26). The gene discussed is CD274; the disease is neoplasm.